ClinicalTrials.gg
RecruitingNCT07560488Updated May 1, 2026

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Bevacizumab Biosimilar IBI305 and ipilimumab N01 in HCC - Hepatocellular Carcinoma and Conversion Therapy, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies testing sintilimab in Carcinoma, Hepatocellular — 27 open to participants now, 31 under way, 5 of them phase 3. sintilimab · Carcinoma, Hepatocellular.

Planned enrollment
27th of 52
43 · median 44
Started
2026
with 4 others
Phase 2
30 of 52
15 open now
Primary completion
2027-04
later than 22 of 30 live
Registered
50th of 52
by date
Lead sponsor
8 of 52
Tianjin Medical University Cancer Institute and Hospital

Among the 52 studies testing sintilimab in Carcinoma, Hepatocellular, this one is the 27th largest by planned enrollment, is one of 5 that started in 2026, is one of 30 in phase 2, reaches primary completion later than 22 of the 30 other live ones, and was the 50th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

27 of the 52 studies testing sintilimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing sintilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Conversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates.

This prospective, single-arm phase II study evaluates a combination regimen of PD-1 inhibitor (sintilimab) plus CTLA-4 inhibitor (ipilimumab N01), bevacizumab biosimilar, and HAIC for patients with initially unresectable intermediate-advanced HCC. The primary goal is to achieve a higher surgical conversion rate with manageable safety

03

Conditions studied

  • HCC - Hepatocellular Carcinoma
  • Conversion Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be signed prior to initiation of any study-related procedures;
  • Age ≥ 18 years, and ≤75 years, regardless of gender;
  • Clinically diagnosed or histologically/ confirmed hepatocellular carcinoma (HCC) according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition);
  • No prior anti-tumor therapy for HCC before study treatment
  • Unresectable locally advanced or advanced HCC (CNLC Stage IIa-IIIb).
  • Expected overall survival > 6 months.
  • (ECOG) performance status score of 0 or 1.
  • score class A or B
  • Adequate organ function defined by the following laboratory parameters:

    1. (ANC) ≥ 1.5×10⁹/L without granulocyte colony-stimulating factor support within 14 days;
    2. count ≥ 80×10⁹/L without transfusion within 14 days;
    3. > 9 g/dL without transfusion or erythropoietin within 14 days;
    4. Total ≤ 1.5× (ULN); or total bilirubin > ULN with direct bilirubin ≤ ULN;
    5. (AST) and alanine aminotransferase (ALT) ≤ 3×ULN;
    6. Serum creatinine ≤ 1.5×ULN and (calculated by Cockcroft-Gault formula) ≥ 60 mL/min;
    7. Adequate coagulation function defined as (INR) or prothrombin time (PT) ≤ 1.5×ULN;
    8. Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible;
    9. Myocardial enzymes within normal limits; isolated laboratory abnormalities deemed clinically insignificant by the investigator are permitted.
  • Female subjects of must have a negative urine or serum pregnancy test within 3 days before the first dose of study drug (Day 1 of Cycle 1). A blood pregnancy test is required if the urine test is inconclusive; They must agree to use adequate during the study period and for 8 weeks after the last dose of study drug;
  • All subjects (male or female) of must use a highly effective contraceptive method with an annual failure rate \< 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.

Exclusion criteria

Exclusion Criteria:

  • Target disease exceptions:

    1. Fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma.
    2. Recurrent HCC.
    3. Clinically diagnosed hepatic encephalopathy within the most recent 6 months.
  • hepatitis (requiring liver confirmation);
  • History of organ transplantation or history of hepatic encephalopathy;
  • Diffuse hepatocellular carcinoma;
  • Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage;
  • History of any renal disease or nephrotic syndrome.
  • Variceal bleeding (esophageal or gastric varices) due to portal hypertension within the past 6 months;severe (Grade 3) varices on endoscopy within 3 months before first dose;evidence of portal hypertension (e.g., splenomegaly >10 cm in longest diameter with \<100×10⁹/L on imaging) with high bleeding risk as assessed by the investigator;
  • Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, , pulmonary embolism, deep vein thrombosis, or other severe thromboembolism.Excluded are catheter-related or port-related thrombosis or superficial venous thrombosis that is stable with standard anticoagulation;
  • Severe bleeding tendency or coagulopathy, or ongoing thrombolytic therapy;
  • Prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is permitted; vitamin K antagonists (e.g., warfarin) are excluded;
  • Long-term use of anti-platelet agents including aspirin, dipyridamole, clopidogrel, or other similar medications;
  • Uncontrolled hypertension despite optimal medical management (systolic BP >140 mmHg or diastolic BP >90 mmHg); history of hypertensive crisis or hypertensive encephalopathy;
  • Symptomatic congestive heart failure ( Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long syndrome or QTcF >500 ms at screening;
  • History of gastrointestinal perforation and/or fistula within the past 6 months; history of bowel obstruction (including partial obstruction requiring parenteral nutrition); extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea;
  • Major surgical procedure (cranial, thoracic, or abdominal) within 4 weeks before first dose, or non-healing wounds, ulcers, or fractures.Core needle biopsy or minor surgery within 7 days before first dose is excluded, except for venous catheter placement for intravenous access;
  • History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction;
  • Acute or chronic active or C infection:HBV DNA >2000 IU/mL or 10⁴ copies/mL; >10³ copies/mL;coinfection with HBsAg and anti-HCV antibody;
  • Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose;
  • (HIV) infection (positive HIV 1/2 antibody) or active syphilis;
  • Active or poorly controlled severe infection; severe infection requiring hospitalization (including sepsis, bacteremia, or severe pneumonia) within 4 weeks before first dose;
  • Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, , or ) within 2 years before first dose.Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal/pituitary insufficiency) is permitted.History of primary immunodeficiency.Subjects with isolated positive autoimmune antibodies will be evaluated at the investigator's discretion;
  • Systemic immunosuppressive drugs within 4 weeks before first dose, excluding topical, inhaled, or intranasal corticosteroids or physiological systemic corticosteroids (≤10 mg/day prednisone or equivalent).Temporary corticosteroids for acute dyspnea in asthma or are permitted;
  • within 4 weeks before first dose or planned use during the study period;
  • Chinese herbal medicine with anti-tumor indications, or immunomodulatory agents (including thymosin, interferon, interleukin) within 2 weeks before first dose, except for local administration for pleural effusion or ascites;
  • Uncontrolled or irreversible metabolic disorders, other acute or chronic non-malignant organ diseases, systemic illnesses, or paraneoplastic syndromes that may increase medical risk or confound survival assessment;
  • Diagnosis of another within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed >5 years before enrollment, pathological or cytological confirmation of recurrent/ lesions is required;
  • Prior treatment with , anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors;
  • Known to sintilimab, bevacizumab, ipilimumab N01 or their , or severe hypersensitivity to other monoclonal antibodies;
  • Participation in another interventional clinical trial within 4 weeks before first dose;
  • Female subjects who are pregnant or breastfeeding;
  • Any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory values that may increase risks associated with study participation or study drug administration, or interfere with the interpretation of study results, and that, in the investigator's judgment, render the patient ineligible for participation in this study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Ipilimumab N01+Sintimab+Bevacizumab+HAIC

    Drug: Bevacizumab Biosimilar IBI305 · Drug: ipilimumab N01 · Drug: Sintilimab · Drug: HAIC

Interventions

  • DrugIBI305Studies of IBI305IBI305 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    7.5 mg/kg, iv, q3w, 3 cycles (discontinue 1 week before surgery)

  • 3mg/kg, iv, q6w, 2 cycles

  • 200mg, iv, q3w, 4 cycles

  • DrugHAIC

    FOLFOX-HAIC, q3w, 4 cycles

This study also gives IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Conversion resection rate

    The percentage of initially unresectable patients who underwent curative resection after protocol-specified conversion therapy.

    Time frame: up to 1 year

Secondary outcomes

  1. Objective response rate

    the percentage of participants in the analysis population who had a CR(Disappearance of all target lesions) or a PR (≥30% decrease in SOD of target lesions) usingRECIST1.1 based oninvestiqator assessment

    Time frame: up to 1 year

  2. R0 Resection Rate

    Proportion of patients achieving complete tumor resection with microscopically negative margins after successful conversion therapy

    Time frame: up to 1 year

  3. Pathological Complete Response

    The proportion of patients in whom no residual viable tumor cells are detected upon histopathological examination of the surgically resected specimen.

    Time frame: up to 1 year

  4. Overall survival

    OS was defined as the time from the first dose of study drug to death due to anycause.

    Time frame: up to 3 years

  5. Treatment-Related Adverse Events (TRAE)

    Treatment-Related Adverse Events (TRAE) as assessed by CTCAE v5.0, including serious adverse events (SAE)

    Time frame: up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 13 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
May 1, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560488
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Mar 30, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 1, 2026

Study contacts

Huikai Li, Prof.
Contact
18526812877@163.com
+8618526812877

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab N01 · Sintilimab · Ipilimumab

Start the discussion